<?xml version="1.0" encoding="UTF-8"?>
<p>Ganciclovir is indicated for the treatment of CMV, particularly for systemic and ocular infections in immunosuppressed patients (
 <xref rid="B25" ref-type="bibr">Buhles et al., 1988</xref>; 
 <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). However, ganciclovir has also been reported to have antiviral activity against HSV-1 and HSV-2 and may be used for the treatment of herpetic keratitis (
 <xref rid="B172" ref-type="bibr">Smee et al., 1983</xref>; 
 <xref rid="B124" ref-type="bibr">Matthews and Boehme, 1988</xref>; 
 <xref rid="B36" ref-type="bibr">Chou and Hong, 2014</xref>). At present, there is an ongoing clinical study that is recruiting patients for assessing the effects of oral ganciclovir, together with femtosecond laser-assisted corneal debridement in the treatment of herpes simplex virus epithelial keratitis (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> NCT03217474). Of note, ganciclovir has been reported to produce considerable adverse side effects in a high percentage of individuals (
 <xref rid="B92" ref-type="bibr">Kimberlin and Whitley, 2007</xref>), such as nephrotoxicity, neutropenia, myelosuppression, confusion, altered mental status, anxiety, ataxia, tremors, convulsions, fever, abnormal levels of liver enzymes in serum, diarrhea, and nausea, among others (
 <xref rid="B92" ref-type="bibr">Kimberlin and Whitley, 2007</xref>).
</p>
